<DOC>
	<DOCNO>NCT01972022</DOCNO>
	<brief_summary>First prospective randomize control study evaluate 'all-comers ' population coronary artery disease whether treatment novel everolimus elute stent ( EES ) biodegradable polymer superior durable polymer zotarolimus elute stent ( ZES ) , respect long term vascular response treatment These data important ascertain superiority new generation DES bioabsorbable polymer coat reduce long term development in-stent neoatherosclerosis .</brief_summary>
	<brief_title>TRANSFORM OCT TRiple Assessment Neointima Stent FOrmation Reabsorbable polyMer With Optical Coherence Tomography</brief_title>
	<detailed_description>During last decade considerable clinical experience accumulate use drug elute coronary stent durable polymer , permanently cover metallic stent scaffold , allow local delivery anti-restenotic agent . However durable polymer associate increased risk late late stent thrombosis anticipate development stent neo-atherosclerosis . Since permanent polymer coating may pro-inflammatory effect , delay heal prolonged endothelial dysfunction , current research DES focus use biodegradable polymer coating , disappear short period drug-release ( 3-4 month ) . Current clinical guideline recommend least 6-12 month dual antiplatelet therapy ( DAPT ) DES implantation , order prevent ST . Recent data obtain pooled analysis ZES , support significant reduction DAPT range use bare metal stent . The substantial delay DES heal observed multiple human pathology series in-vivo study use Optical Coherence Tomography ( OCT ) assess risk factor prolong use DAPT . However different patient cohort might different response stent implantation . In addition , comparative evidence long term development neo-atherosclerosis bioabsorbable versus permanent polymer DES . OCT allow precise assessment stent strut apposition coverage accurate measure different tissue component neoatherosclerosis . This study first attempt characterize early late vascular response novel bioabsorbable polymer EES ( SYNERGY™ ) compare permanent polymer benchmark novel generation ZES ( RESOLUTE INTEGRITY™ ) .The stent comparator select due large use across interventional cardiology community recent approval European Regulators Authorities update CE ( Conformité Européenne ) mark label one-month duration dual anti-platelet therapy .</detailed_description>
	<criteria>1 . Subject ≥18 year age ; 2 . Subject stable angina acute coronary syndrome ( include acute myocardial infarction ) evidence coronary ischemia de novo atherosclerotic coronary artery disease multiple vessel indication stent implantation ; 3 . Target lesion stenosis ≥ 70 % ( visual estimate ) 4 . All target lesion require treatment stent diameters 2.25 mm 4.0 mm ( visual estimate ) 5 . Target lesion length ≥10 mm ≤50 mm target lesion ( ) 6 . Subject must sign Ethics Committee approve informed consent prior undergo study specific procedure ; 7 . Subject must willing able comply specify followup schedule . 1 . Unprotected leave main coronary disease ; 2 . Chronic total occlusion ; 3 . Severe calcify target lesion ( ) , investigator 's opinion , successfully treat ; 4 . Significant angulation target vessel , Investigator 's opinion , may preclude stent delivery deployment ; 5 . Bifurcation disease involve side branch ≥ 2.5 mm diameter ; 6 . Restenotic lesion ; 7 . Target lesion ( ) within coronary bypass graft ( e.g. , saphenous vein arterial graft ) ; 8 . In Investigator 's opinion , lesion suitable stenting OCT imaging ( e.g . extreme tortuosity , distal lesion ) . 9 . Documented leave ventricular ejection fraction ≤30 % ; 10 . Serum creatinine &gt; 2.0 mg/dl time treatment ; 11 . Recipient heart transplant ; 12 . Subject malignancy comorbidities ( i.e . severe liver , renal , pulmonary , pancreatic disease ) life expectancy le 18 month may result protocol noncompliance ; 13 . Known bleed hypercoagulable disorder ; 14 . Known allergy stent component antiplatelet recommend drug 15 . Planned medical surgical procedure require modification DAPT regimen within 3 month index procedure ; 16 . Women childbearing potential without negative pregnancy test within 7 day enrollment 17 . Currently participate investigational study complete primary endpoint clinically interfere study endpoint</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Drug Eluting Stents</keyword>
	<keyword>Bioabsorbale Polymer Coating</keyword>
	<keyword>Neoatherosclerosis</keyword>
	<keyword>Stent Coverage</keyword>
	<keyword>Stent Failure</keyword>
</DOC>